Needham initiated coverage of BioAge Labs with a Buy rating and $50 price target. The firm is "bullish" on the company's lead asset BGE-102, an oral, NLRP3 inhibitor in Phase 1 development for cardiovascular risk in obese patients. BGE-102's safety and early biomarker data demonstrate "best-in-class potential in a very large indication," the analyst tells investors in a research note. Needham sees a favorable risk/reward for the shares ahead of several catalysts in the next 12-15 months.
